EULAR® 2024 Insights


 

EULAR® 2024 Insights: Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis (PsA) Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks - Data From the FOREMOST Study

14 views
June 26, 2024
Comments 0
Login to view comments. Click here to Login